How to buy Aclaris Therapeutics stock

Aclaris Therapeutics, Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around USD$6.5 million.

How to buy shares in Aclaris Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Aclaris Therapeutics. Find the stock by name or ticker symbol: ACRS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aclaris Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aclaris Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Aclaris Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aclaris Therapeutics share price

Use our graph to track the performance of ACRS stocks over time.

Aclaris Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$1.02 - USD$30.375
50-day moving average	USD$24.5403
200-day moving average	USD$12.4685
Wall St. target price	USD$29.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.168

Buy Aclaris Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aclaris Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aclaris Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aclaris Therapeutics financials

Revenue TTM	USD$6.5 million
Gross profit TTM	USD$-27,989,000
Return on assets TTM	-35.87%
Return on equity TTM	-95.12%
Profit margin	0%
Book value	$0.835
Market capitalisation	USD$1.4 billion

TTM: trailing 12 months

Shorting Aclaris Therapeutics shares

There are currently 911,063 Aclaris Therapeutics shares held short by investors – that's known as Aclaris Therapeutics's "short interest". This figure is 41.5% up from 643,991 last month.

There are a few different ways that this level of interest in shorting Aclaris Therapeutics shares can be evaluated.

Aclaris Therapeutics's "short interest ratio" (SIR)

Aclaris Therapeutics's "short interest ratio" (SIR) is the quantity of Aclaris Therapeutics shares currently shorted divided by the average quantity of Aclaris Therapeutics shares traded daily (recently around 619770.74829932). Aclaris Therapeutics's SIR currently stands at 1.47. In other words for every 100,000 Aclaris Therapeutics shares traded daily on the market, roughly 1470 shares are currently held short.

However Aclaris Therapeutics's short interest can also be evaluated against the total number of Aclaris Therapeutics shares, or, against the total number of tradable Aclaris Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aclaris Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aclaris Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0183% of the tradable shares (for every 100,000 tradable Aclaris Therapeutics shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aclaris Therapeutics.

Find out more about how you can short Aclaris Therapeutics stock.

Aclaris Therapeutics share dividends

We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.

Aclaris Therapeutics share price volatility

Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $1.02 up to $30.375. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.7005. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).

Aclaris Therapeutics overview

Aclaris Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc.

Frequently asked questions

• What percentage of Aclaris Therapeutics is owned by insiders or institutions?

  Currently 8.247% of Aclaris Therapeutics shares are held by insiders and 65.379% by institutions.

• How many people work for Aclaris Therapeutics?

  Latest data suggests 57 work at Aclaris Therapeutics.

• When does the fiscal year end for Aclaris Therapeutics?

  Aclaris Therapeutics's fiscal year ends in December.

• Where is Aclaris Therapeutics based?

  Aclaris Therapeutics's address is: 640 Lee Road, Wayne, PA, United States, 19087

• What is Aclaris Therapeutics's ISIN number?

  Aclaris Therapeutics's international securities identification number is: US00461U1051

• What is Aclaris Therapeutics's CUSIP number?

  Aclaris Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00461U105